SCHOTT Pharma
Dr. Almuth Steinkühler has extensive experience in finance and controlling, with a specialization in the pharmaceutical industry. Dr. Almuth currently holds the position of Chief Financial Officer at SCHOTT Pharma. Prior to this, they served as Vice President Finance & Controlling for the Business Unit Pharma at SCHOTT. Before joining SCHOTT, Dr. Steinkühler worked at thyssenkrupp, where they held the role of Head of Controlling, Accounting & Risk for the Business Unit Chemical and Process Technologies. Dr. Almuth also had various roles at Conveyor Belt Group and Oil & Marine, both part of Continental AG, where they gained experience in operations controlling, commercial management, and investment controlling. Dr. Steinkühler began their career as a Research Assistant at WHU - Otto Beisheim School of Management, focusing on management accounting and control.
Dr. Almuth Steinkühler received their Master of Business Administration (MBA) and Diplom-Kauffrau degree in Controlling, Accounting, and Marketing from WHU – Otto Beisheim School of Management from 2001 to 2005. Dr. Almuth later pursued a Dr. rer. pol. / German PhD in Controllership, focusing on measurement, impact, and determinants, from the same institution from 2005 to 2008.
SCHOTT Pharma
1 followers
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. Every day, more than 4,700 people from 65 nations work at SCHOTT Pharma to contribute to global healthcare. The company has 17 manufacturing sites across major pharmaceutical hubs in Europe, the Americas and Asia. SCHOTT Pharma maintains a diverse portfolio of injectable drug containment and delivery solutions. These solutions range from prefillable glass and polymer syringes, cartridges, vials and ampoules. The company has focused on developing innovations for future technologies by: • Creating over 1000 patents and technologies developed in-house • Building a state-of-the-art Research and Development Center in Switzerland • Absorbing over 130 professionals focused on Research and Development Despite being a pharmaceutical manufacturer, SCHOTT Pharma aims to become climate-neutral by 2030. The company commits to this through sustainable development approaches in the society and the environment. Based in Mainz, Germany, it is part of SCHOTT AG that falls under the Carl Zeiss Foundation. SCHOTT Pharma has over 1700 global customers, 30 of which are the leading pharmaceutical manufacturers of injectable drugs. These customers have generated combined sales of EUR 899 million in the fiscal year 2023. Contact us now: pharma@schott.com Data protection: https://www.schott-pharma.com/en/legal-social